Jamil Khurram sold $262K of GALT
Jamil Khurram (Chief Medical Officer) sold 52,037 shares of GALECTIN THERAPEUTICS INC (GALT) at an average of $5.04 ($5.00–$5.04, $0.26M total) across 3 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed sale size, price range, and post-sale holdings (0 shares) under a pre-arranged 10b5-1 plan; this typically has limited fundamental impact but can influence short-term sentiment.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is primarily a planned liquidity event rather than new company fundamentals.
What to watch
10b5-1 plans can be executed regardless of outlook; without accompanying changes in guidance/clinical/regulatory milestones, the filing is unlikely to be a standalone catalyst.
Background
The article is an SEC Form 4 insider transaction disclosure for GALECTIN THERAPEUTICS, reported by its Chief Medical Officer.
Ticker impact
SEC Form 4 shows CMO Jamil Khurram sold 52,037 shares of GALECTIN THERAPEUTICS at ~$5.04 via a 10b5-1 plan, leaving 0 shares.
Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived.
The disclosure is an open-market sale under a pre-arranged 10b5-1 plan, with the insider ending with 0 shares—more consistent with planned liquidity than new negative information.
Market effects
No direct sector read-through; this is company-specific insider liquidity rather than regulatory/clinical/financing news.
None indicated.
None indicated.
Counterpoint
Because the insider sold down to zero, some traders may still interpret it as a stronger-than-usual signal despite the 10b5-1 label.
Key entities
- companyGALECTIN THERAPEUTICS INC
Issuer of the Form 4 insider transaction disclosed in the article.
- insiderJamil Khurram
Chief Medical Officer who sold 52,037 shares via open-market transactions under a 10b5-1 plan.